Receptor targeted
chemotherapy is less toxic and more effective than conventional
chemotherapy. Receptors for
luteinizing hormone-releasing hormone (
LH-RH) are found in about 50% of human breast
cancers. Highly potent cytotoxic radical
2-pyrrolinodoxorubicin (AN-201) was linked to the agonistic analog [D-Lys6]
LH-RH to form cytotoxic
LH-RH analog
AN-207. We evaluated whether
AN-207 could be targeted to the
hormone-independent MDA-MB-231 human breast
cancers. Nude mice bearing MDA-MB-231
tumors were injected i.v. with 250 nmol/kg doses of cytotoxic radical
AN-201, cytotoxic
LH-RH analog
AN-207, the unconjugated mixture of
AN-201 and carrier [D-Lys6]
LH-RH, [D-Lys6]
LH-RH alone and vehicle (control). The growth of MDA-MB-231
tumors in animals given a single dose of
AN-207 was inhibited significantly (p = 0.01) for 3 weeks after injection, whereas
tumors in all the other groups grew steadily. All cytotoxic compounds produced
leukopenia, but the strongest lymphocyte suppression was caused by cytotoxic radical
AN-201. Three weeks
after treatment, the presence of
mRNA for
LH-RH receptors was demonstrated by RT-PCR in all the groups and radioreceptor assays demonstrated high-affinity binding sites for
LH-RH on
tumor cell membranes of control animals and those treated with
AN-201, the carrier
peptide alone or in combination with
AN-201. At this time point binding assays did not reveal the expression of
membrane proteins in
tumors treated with
AN-207, but 60 days after administration of
AN-207, high affinity
LH-RH binding sites were found again in MDA-MB-231
tumors. These results indicate that cytotoxic
LH-RH analog
AN-207 could be utilized for receptor targeted
chemotherapy of breast
cancers expressing receptors for
LH-RH.